Wall Street Journal. Europe 2001 Vanessa. Fuhrmans - Abstracts

Wall Street Journal. Europe 2001 Vanessa. Fuhrmans
TitleSubjectAuthors
Allianz-Dresdner deal may trigger business revolution.Business, internationalChristopher Rhoads, Vanessa Fuhrmans, Marcus Walker
Aventis Expects Existing Drugs To Fuel Growth.(Aventis S.A. reports loss of $147 mn in Euro dollars for 2000)Business, internationalVanessa Fuhrmans, Gautum Naik
BASF warns 1st-half growth will be 'somewhat subdued.'Business, internationalVanessa Fuhrmans
Baxter to purchase oncology business from Degussa.(Firm makes its first big push into cancer-treatment market.)Business, internationalVanessa Fuhrmans
Bayer and CuraGen will study, develop small-molecule drugs.Business, internationalVanessa Fuhrmans, Scott Hensley
Bayer emerges as front-runner for Aventis unit.Business, internationalAnita Raghavan, Vanessa Fuhrmans
Bayer plans to buy unit from Aventis for 5.5 billion euros.Business, internationalVanessa Fuhrmans
Bayer's operating earnings fell 45% in second quarter.(Company to cut 1,800 jobs and close 18 chemical plants.)Business, internationalVanessa Fuhrmans
Bayer to sell Agfa-Gevaert stake to shed nonstrategic activities.Business, internationalVanessa Fuhrmans
Drug makers' results offer hope, but investors demur.(GlaxoSmithKline, Serono post healthy second-quarter earnings.)Business, internationalVanessa Fuhrmans
European panel will review cholesterol-lowering drugs.(Decision comes a day after Baycol withdrawal.)Business, internationalVanessa Fuhrmans
Germany's bitter ethics debate.(embryonic stem cells debate in Germany)Business, internationalVanessa Fuhrmans
Lesson in alienation: How Bayer angered a captive market.Business, internationalVanessa Fuhrmans
Novartis buys 20% stake in Roche for C3.12 billion (Euro dollars).Business, internationalVanessa Fuhrmans
Roche and Decode make progress on gene findings.(Firms target schizophrenia, narrowing of arteries.)Business, internationalVanessa Fuhrmans
Roche, DeCODE set research pact.Business, internationalVanessa Fuhrmans
Roche fires its CFO over lack of chemistry.Business, internationalVanessa Fuhrmans
Roche posts 2% drop in drug sales.Business, internationalVanessa Fuhrmans, Anita Greil
Roche sees operating margin shrinking this year (Roche Holding AG).Business, internationalVanessa Fuhrmans
Roche weighs cost-cutting plan to boost ailing drug division.Business, internationalVanessa Fuhrmans
Roche will cut 3,000 jobs in pharmaceuticals division.Business, internationalVanessa Fuhrmans
Sulzer Ltd. chairman steps down, citing hostile takeover bid.(InCentive Capital's offer focuses criticism on roost.)Business, internationalVanessa Fuhrmans, Anita Greil
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.